Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona zgoda pacjenta lub opiekuna prawnego na udział w badaniu
- •Zarejestrowanie w programie Revlimid REMS
- •Stan sprawności fizycznej ECOG 0-2 (pacjent może wykonywać codzienne czynności)
- •Całkowite ustąpienie ostrych działań niepożądanych poprzednich leczeń (oprócz utraty włosów)
- •Potwierdzony nawrót lub brak odpowiedzi na poprzednie leczenie
- •Wcześniejszy brak skuteczności co najmniej 2 poprzednich systemowych terapii
- •Potwierdzenie rozpoznania pod mikroskopem w ciągu ostatnich 6 miesięcy
- •Wystarczająca liczba neutrofili (białych krwinek) i płytek krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
City of Hope Medical Center
Duarte, United States
Memorial Sloan-Kettering Cancer Center
New York, United States
Thomas Jefferson University Hospital
Philadelphia, United States
M D Anderson Cancer Center
Houston, United States
Trial contact
Christiane Querfeld, MD
Christiane Querfeld, MD
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.